| Risk adjustor variables | Population frequency | Base model | Constrained model |
|---|---|---|---|
| Intercept | 100.00% | 203 | −790 |
| Male. 0 | 0.55% | 3716 | 5898 |
| Male. 1–4 | 2.27% | 425 | −85 |
| Male. 5–9 | 2.96% | 289 | −72 |
| Male. 10–14 | 3.11% | 172 | 410 |
| Male. 15–17 | 1.81% | 192 | 629 |
| Male. 18–24 | 4.29% | −15 | −38 |
| Male. 25–29 | 2.94% | −42 | −58 |
| Male. 30–34 | 2.95% | −39 | −34 |
| Male. 35–39 | 3.08% | 0 | 0 |
| Male. 40–44 | 3.83% | 75 | 114 |
| Male. 45–49 | 3.89% | 187 | 263 |
| Male. 50–54 | 3.67% | 333 | 499 |
| Male. 55–59 | 3.33% | 584 | 936 |
| Male. 60–64 | 3.19% | 813 | 1364 |
| Male. 65–69 | 2.73% | 1278 | 1643 |
| Male. 70–74 | 1.90% | 1661 | 2041 |
| Male. 75–79 | 1.37% | 2104 | 2401 |
| Male. 80–84 | 0.89% | 2248 | 2351 |
| Male. 85–89 | 0.43% | 2364 | 2105 |
| Male. 90+ | 0.15% | 2542 | 1433 |
| Female. 0 | 0.52% | 3069 | 5207 |
| Female. 1–4 | 2.17% | 199 | −154 |
| Female. 5–9 | 2.82% | 153 | 158 |
| Female. 10–14 | 2.97% | 142 | 514 |
| Female. 15–17 | 1.72% | 324 | 416 |
| Female. 18–24 | 4.18% | 305 | 145 |
| Female. 25–29 | 2.96% | 774 | 985 |
| Female. 30–34 | 2.99% | 935 | 1549 |
| Female. 35–39 | 3.14% | 546 | 977 |
| Female. 40–44 | 3.83% | 309 | 439 |
| Female. 45–49 | 3.86% | 352 | 387 |
| Female. 50–54 | 3.68% | 463 | 578 |
| Female. 55–59 | 3.34% | 573 | 773 |
| Female. 60–64 | 3.18% | 733 | 1110 |
| Female. 65–69 | 2.78% | 1043 | 1162 |
| Female. 70–74 | 2.07% | 1362 | 1534 |
| Female. 75–79 | 1.71% | 1703 | 2019 |
| Female. 80–84 | 1.37% | 1955 | 2296 |
| Female. 85–89 | 0.89% | 2165 | 2341 |
| Female. 90+ | 0.48% | 2125 | 1181 |
| No PCG a | 82.03% | 201 | 637 |
| Glaucoma | 0.85% | 279 | 346 |
| Thyroid disorders | 1.64% | 83 | −181 |
| Mental disorders | 0.53% | 95 | 1243 |
| Depressive disorder | 2.67% | 184 | −636 |
| Peripheral neuropathy | 0.38% | 1159 | 157 |
| Hypercholesterolemia | 5.30% | 178 | −620 |
| Diabetes II without hypertension | 0.63% | 531 | −1868 |
| COPD / severe asthma | 1.16% | 1565 | 1165 |
| Asthma | 2.16% | 573 | 643 |
| Diabetes II with hypertension | 1.40% | 845 | −1511 |
| Epilepsy | 0.48% | 834 | −245 |
| Crohn’s disease / Colitis ulcerosa | 0.20% | 818 | 2881 |
| Heart diseases | 2.21% | 1500 | 1242 |
| Rheumatoid arthritis (TNF-α) | 0.19% | 14164 | 14623 |
| Rheumatoid arthritis (other) | 0.32% | 1478 | 2813 |
| Parkinson’s disease | 0.14% | 2176 | 3527 |
| Diabetes type I | 1.29% | 1361 | 649 |
| Transplantations | 0.15% | 89 | 6361 |
| Cystic fibrosis / Pancreatic disease | 0.04% | 3021 | 15999 |
| Disorders of brain/ spinal cord | 0.07% | 1511 | 4128 |
| Cancer | 0.09% | 3697 | 9279 |
| Hormone-sensitive tumors | 0.35% | −712 | −2226 |
| HIV/AIDS | 0.08% | 2826 | 29936 |
| Kidney disorders | 0.07% | 7201 | 15969 |
| No DCG b | 91.00% | 0 | 0 |
| DCG1 | 0.67% | 391 | 400 |
| DCG2 | 1.49% | 560 | 750 |
| DCG3 | 1.11% | 635 | 659 |
| DCG4 | 1.80% | 1011 | 3436 |
| DCG5 | 1.16% | 1618 | 2657 |
| DCG6 | 1.26% | 2002 | 3813 |
| DCG7 | 0.55% | 3225 | 9061 |
| DCG8 | 0.12% | 3989 | 9721 |
| DCG9 | 0.30% | 3847 | 6950 |
| DCG10 | 0.33% | 7307 | 14332 |
| DCG11 | 0.04% | 8722 | 14286 |
| DCG12 | 0.07% | 8608 | 20788 |
| DCG13 | 0.04% | 15876 | 32097 |
| DCG14 | 0.04% | 65152 | 63374 |
| DCG15 | 0.01% | 51005 | 140811 |
| ZIP-code cluster 1 | 9.91% | 169 | 479 |
| ZIP-code cluster 2 | 9.88% | 124 | 351 |
| ZIP-code cluster 3 | 9.97% | 101 | 254 |
| ZIP-code cluster 4 | 9.86% | 84 | 215 |
| ZIP-code cluster 5 | 10.01% | 68 | 203 |
| ZIP-code cluster 6 | 9.91% | 64 | 171 |
| ZIP-code cluster 7 | 9.98% | 50 | 129 |
| ZIP-code cluster 8 | 9.98% | 38 | 78 |
| ZIP-code cluster 9 | 10.17% | 24 | 44 |
| ZIP-code cluster 10 | 10.32% | 0 | 0 |
| Age = 0–17 or 65+ | 37.67% | 0 | 0 |
| Disability beneficiaries. 15–34 | 0.91% | 647 | −969 |
| Disability beneficiaries. 34–44 | 0.77% | 803 | −50 |
| Disability beneficiaries. 45–54 | 1.30% | 720 | 88 |
| Disability beneficiaries. 55–64 | 2.02% | 596 | 362 |
| General beneficiaries. 15–34 | 0.57% | 267 | −260 |
| General beneficiaries. 34–44 | 0.55% | 353 | −214 |
| General beneficiaries. 45–54 | 0.60% | 412 | 43 |
| General beneficiaries. 55–64 | 0.48% | 368 | 327 |
| Students. 18–34 | 3.20% | −238 | −233 |
| Self-employed. 15–34 | 0.78% | −116 | −155 |
| Self-employed. 34–44 | 1.27% | −111 | −112 |
| Self-employed. 45–54 | 1.32% | −146 | −156 |
| Self-employed. 55–64 | 0.79% | −152 | −148 |
| Other. 15–34 | 14.84% | 0 | 0 |
| Other. 34–44 | 11.29% | 0 | 0 |
| Other. 45–54 | 11.88% | 0 | 0 |
| Other. 55–64 | 9.75% | 0 | 0 |
| No MYHCG c | 94.24% | 0 | 0 |
| 2x costs in top-10% | 1.01% | 2661 | 6082 |
| 3x costs in top-15% | 2.30% | 2318 | 3155 |
| 3x costs in top-10% | 1.05% | 3680 | 4370 |
| 3x costs in top-7% | 0.78% | 5692 | 6085 |
| 3x costs in top-4% | 0.46% | 9661 | 9066 |
| 3x costs in top-1.5% | 0.15% | 25836 | 37142 |
| No DMECG d | 99.17% | 0 | 0 |
| Insulin pumps | 0.12% | 422 | −3319 |
| Catheters | 0.39% | 1308 | −1212 |
| Stoma | 0.31% | 1801 | −929 |
| Trachea-stoma | 0.02% | 6546 | 2464 |
| Address >15 residents. 0–17 | 0.06% | 244 | −1059 |
| Address >15 residents. 18–64 | 0.38% | 169 | 480 |
| Address >15 residents. 65+ | 0.72% | 321 | 5820 |
| Income deciles 1–3. 0–17 | 6.25% | 27 | −110 |
| Income deciles 1–3. 18–64 | 18.57% | 53 | 12 |
| Income deciles 1–3. 65+ | 4.81% | 200 | −269 |
| Income deciles 4–7. 0–17 | 8.34% | −5 | −115 |
| Income deciles 4–7. 18–64 | 24.79% | 48 | 23 |
| Income deciles 4–7. 65+ | 6.41% | 44 | −166 |
| Income deciles. 8–10. 0–17 | 6.25% | 0 | 0 |
| Income deciles. 8–10. 18–64 | 18.59% | 0 | 0 |
| Income deciles. 8–10. 65+ | 4.81% | 0 | 0 |
| 65-. no morbidity e | 70.38% | 0 | 0 |
| 65-. morbidity | 12.86% | 618 | 1541 |
| 65+. no morbidity | 6.89% | 0 | 0 |
| 65+. morbidity | 9.88% | 642 | 2272 |
PCG = Pharmacy-based Cost Group
DCG = Diagnostic-based Cost Group
MYHCG = Multiple-Year High Cost Group
DMECG = Durable Medical Equipment Cost Group
Morbidity is operationalized as having at least one PCG, DCG, MYHCG or DMECG.